Online Only Articles

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
Institut de Recherches Servier, Suresnes, France
Institut de Recherches Servier, Suresnes, France
Institut de Recherches Servier, Suresnes, France
Institut de Recherches Servier, Suresnes, France
Institut de Recherches Servier, Suresnes, France
Novartis Institutes for Biomedical Research, Cambridge, MA, USA
Novartis Institutes for Biomedical Research, Basel, Switzerland
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain
University Hospital of Salamanca (IBSAL)-Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain;University Hospital Marqués de Valdecilla (IDIVAL); University of Cantabria, Santander, Spain
Vol. 105 No. 3 (2020): March, 2020 https://doi.org/10.3324/haematol.2018.212308